Domainex

Activities: Research & Development

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. ISCC 15-18 October 2024 | Conference | Milan, Italy
  3. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. PROFINET enables the seamless integration of Watson-Marlow pumps into Kühner single-use bioreactors A PROFINET interface has enabled the seamless integration of Watson-Marlow 630PnN/R and 730PnN/R pumps into the Siemens environment of Adolf Kühner AG’s SB2500-Z orbital...

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Design & Build

New biology centre opened by HM Lord-Lieutenant of Cambridgeshire

The new three-storey facility provides over 24,000 sqft for Domainex’s expanding biology/bioanalytical departments
Drug Delivery

Amphista Therapeutics partners with Domainex drug discovery portfolio

Domainex has experience in the field of TPD with expertise in designing, synthesising, and profiling targeted heterobifunctional protein degraders
Finance

Domainex acquires more than £1m of Waters equipment

The SQ detectors will enable Domainex to increase its capacity to analyse and purify compounds with higher molecular masses
Research & Development

Domainex opens dedicated facility at Unity Campus

“The investment into our new facility has allowed us to create a fully dedicated suite of labs to conduct our biology services”
Drug Delivery

Parkinson’s UK and Domainex collaborate on inflammation therapy

The organisations plan to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s
Research & Development

Queen’s University Belfast enters FLIP inhibitor collaboration

The university will work with Ipsen on the inhibitors, which have been supported by Domainex
Research & Development

Expanding the medicinal chemist’s toolbox

Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Subscribe now